Search results for "registry"

showing 10 items of 273 documents

Completeness and timeliness: Cancer registries could/should improve their performance.

2015

Abstract Cancer registries must provide complete and reliable incidence information with the shortest possible delay for use in studies such as comparability, clustering, cancer in the elderly and adequacy of cancer surveillance. Methods of varying complexity are available to registries for monitoring completeness and timeliness. We wished to know which methods are currently in use among cancer registries, and to compare the results of our findings to those of a survey carried out in 2006. Methods In the framework of the EUROCOURSE project, and to prepare cancer registries for participation in the ERA-net scheme, we launched a survey on the methods used to assess completeness, and also on t…

CompletenessCancer ResearchTime FactorsCancer registry Completeness Timeliness Flow methodPopulationFlow methodDeath CertificatesNOMedian latencyCause of DeathNeoplasmsMedicineHumansRegistrieseducationeducation.field_of_studybusiness.industryInformation DisseminationData CollectionIncidenceComparabilityTimelinessFlow methodCancer registrymedicine.diseaseQuality ImprovementCancer registryEuropeOncologyPopulation SurveillanceMedical emergencyDeath certificatebusinessCompleteness (statistics)European journal of cancer (Oxford, England : 1990)
researchProduct

Applicability of the Poisson distribution to model the data of the German Children's Cancer Registry.

1995

Since 1980 the German Children's Cancer Registry has documented all childhood malignancies in the Federal Republic of Germany. Various statistical procedures have been proposed to identify municipalities or other geographic units with increased numbers of malignancies. Usually the Poisson distribution, which requires the malignancies to be distributed homogeneously and uncorrelated, is applied. Other discrete statistical distributions (so-called cluster distributions) like the generalized or compound Poisson distributions are applicable more generally. In this paper we present a first explorative approach to the question of whether it is necessary to use one of these cluster distributions t…

Computer scienceBiophysicsPoisson distributionDisease clusterGermansymbols.namesakeGermanyNeoplasmsStatisticsEconometricsHumansPoisson DistributionRegistriesChildGeneral Environmental ScienceProbabilityRadiationModels StatisticalGermany WestFederal republic of germanylanguage.human_languageUncorrelatedCancer registrysymbolslanguageProbability distributionRadiation and environmental biophysics
researchProduct

Rationale, design and methods of CTCA-PRORECAD (Computed Tomography Coronary Angiography Prognostic Registry for Coronary Artery Disease): a multicen…

2013

PURPOSE: This study was done to assess the prognostic value of computed tomography coronary angiography (CTCA) in a large multicentre population of patients with suspected coronary artery disease (CAD) and, in particular, its incremental value compared with traditional methods for risk stratification. MATERIALS AND METHODS: This is a retrospective observational study that began in January 2003 conducted on patients with suspected CAD assessed with CTCA on the basis of symptoms (chest pain, dyspnoea) and/or abnormal or equivocal stress test and/or a high cardiovascular risk profile. The participating centres will provide data obtained with CTCA performed with 16-slice or higher equipment. Ex…

Coronary angiographyMaleContrast MediaComputed tomographyCoronary DiseaseCoronary AngiographyCoronary artery diseaseComputed tomography coronary angiographyCoronary artery diseaseComputer-AssistedRisk FactorsRegistriesTomographyNeuroradiologyeducation.field_of_studymedicine.diagnostic_testcomputed tomography coronary angiography; coronary artery disease; prevalence of disease; prognosis; registry; risk stratificationRadiographic Image InterpretationInterventional radiologyGeneral MedicineMiddle AgedPrognosisX-Ray ComputedResearch DesignRisk stratificationCardiologyPrevalence of diseaseRadiographic Image Interpretation Computer-AssistedFemaleRadiologymedicine.medical_specialtyRegistryPrognosiEndpoint DeterminationPopulationRisk AssessmentComputed tomography coronary angiography; Coronary artery disease; Prevalence of disease; Prognosis; Risk stratification; Registry; Analysis of Variance; Contrast Media; Coronary Disease; Endpoint Determination; Female; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Radiographic Image Interpretation Computer-Assisted; Retrospective Studies; Risk Assessment; Risk Factors; Coronary Angiography; Registries; Research Design; Tomography X-Ray ComputedInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingeducationRisk stratificationProportional Hazards ModelsRetrospective StudiesAnalysis of Variancebusiness.industrymedicine.diseasebusinessTomography X-Ray ComputedLa Radiologia medica
researchProduct

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

2020

Abstract Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. Methods MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. Results We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group,…

Coronavirus COVID-19 Pneumonia SARS-CoV-2 TocilizumabGCA Giant cell arteritispJIA Pediatric juvenile idiopathic arthritislaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawMedicine030212 general & internal medicineClinical efficacyCPAP Continuous positive airway pressureCOVID-19 Coronavirus disease 2019IDSA Infectious Diseases Society of AmericaRA Rheumatoid arthritisTocilizumabIMV Invasive mechanical ventilationsJIA Juvenile idiopathic arthritisAIFA Agenzia Italiana del FarmacoPulmonary and Respiratory Medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINEAntibodies Monoclonal HumanizedNIH U.S. National Institutes of HealthArticleWHO World Health OrganizationSIMIT Italian Society of Infectious and Tropical disease03 medical and health sciencesTocilizumabARDS Acute respiratory distress syndromeAnimalsHumansIn patientIntensive care medicineTocilizumab ; COVID-19 ; Pneumonia ; SARS-CoV-2 ; Coronaviruslcsh:RC705-779business.industryCRS CAR-T cell-induced cytokine release syndromeInterleukin-6SARS-CoV-2NIV Noninvasive mechanical ventilationTNF Tumor necrosis factorCOVID-19Pneumonialcsh:Diseases of the respiratory systemCOVID-19 Drug TreatmentClinical trialCoronavirus030228 respiratory systemchemistrybusinessICTRP International Clinical Trials Registry PlatformPulmonology
researchProduct

Therapeutic options for homozygous familial hypercholesterolemia: the role of Lomitapide

2020

Background:Lomitapide (Juxtapid® in US and Lojuxta® in Europe) is the first developed inhibitor of the Microsomal Triglyceride Transfer Protein (MTP) approved as a novel drug for the management of Homozygous Familial Hypercholesterolemia (HoFH). It acts by binding directly and selectively to MTP thus decreasing the assembly and secretion of the apo-B containing lipoproteins both in the liver and in the intestine.Aims:The present review aims at summarizing the recent knowledge on lomitapide in the management of HoFH.Results:The efficacy and safety of lomitapide have been evaluated in several trials and it has been shown a reduction of the plasma levels of Low-Density Lipoprotein Cholesterol …

Drugmedicine.medical_specialtymedia_common.quotation_subjectFamilial hypercholesterolemia030204 cardiovascular system & hematologyBiochemistryMicrosomal triglyceride transfer proteinHyperlipoproteinemia Type II03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineDrug DiscoveryMedicineHumans030212 general & internal medicinemedia_commonPharmacologybiologybusiness.industryAnticholesteremic AgentsOrganic ChemistryHypertriglyceridemiaPlasma levelsmedicine.diseaseLomitapideEuropeTolerabilitychemistrybiology.proteinMolecular MedicinePancreatitisBenzimidazolesHoFH – Lomitapide – LOWER Registry – MTP inhibition – MTP SNPsbusiness
researchProduct

What is the impact of rerouting a cancer diagnosis from emergency presentation to GP referral on resource use and survival? Evidence from a populatio…

2018

Background Studies on alternative routes to diagnosis stimulated successful policy interventions reducing the number of emergency diagnoses and associated mortality risk. A dearth of evidence on the costs of such interventions might prevent new policies from achieving more ambitious targets. Methods We conducted a retrospective cohort study on the population of colorectal (88,051), breast (90,387), prostate (96,219), and lung (97,696) cancer patients diagnosed after a GP referral or an emergency presentation and reported in the Cancer Registry of England. Resource use and survival were compared 1 year before and 5 years after diagnosis (3 years for lung), including the costs of GP referrals…

Emergency Medical ServicesCancer ResearchSurvival0302 clinical medicineNeoplasmsEmergency medical services1306030212 general & internal medicineMedical diagnosisReferral and Consultationeducation.field_of_study1311Health Care CostsEarly diagnosilcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisEarly diagnosisPrimary careRoute to diagnosisRoute to diagnosiOncologyPopulation Surveillance030220 oncology & carcinogenesisHealth ResourcesHospital costResearch Articlemedicine.medical_specialty2730ReferralEarly diagnosis; Emergency; Hospital costs; Primary care; Route to diagnosis; Survival; Oncology; Genetics; Cancer ResearchPopulationlcsh:RC254-28203 medical and health sciencesGeneticGeneral PractitionersGeneticsmedicineHumanseducationLung cancerbusiness.industryCancerRetrospective cohort studymedicine.diseaseCancer registryEmergency medicineEmergencyHospital costsbusinessNeoplasms/diagnosis
researchProduct

Decrease in annual incidence of acute coronary syndrome and restructuring of coronary care in Latvia

2014

Abstract Introduction Improvement in coronary heart disease prevention and treatment, as well as availability of coronary care facilities, is important for the reduction of acute coronary syndrome (ACS) incidence. Centralized acute coronary care system is crucial to provide optimal hospitalization and management algorithm for ACS patients. Aim The aim of the current report was to assess the annual incidence of ACS and the quality of acute coronary care in Latvia. Methods The Data from The Latvian Registry of Acute Coronary Syndromes were analyzed covering the time period from 2005 to 2010. Results Since the year 2005 the annual incidence of hospitalization due to ACS decreased significantly…

Emergency medical servicesmedicine.medical_specialtyAcute coronary syndromeInvasive strategybusiness.industryIncidence (epidemiology)medicine.medical_treatmentPrimary percutaneous coronary interventionPercutaneous coronary interventionmedicine.diseaseAnnual incidenceManagement algorithmEmergency medicinemedicineEmergency medical servicesRegistry dataAcute coronary syndromeIntensive care medicinebusinessCardiology and Cardiovascular MedicineCor et Vasa
researchProduct

Standards not that standard

2015

There is a general assent on the key role of standards in Synthetic Biology. In two consecutive letters to this journal, suggestions on the assembly methods for the Registry of standard biological parts have been described. We fully agree with those authors on the need of a more flexible building strategy and we highlight in the present work two major functional challenges standardization efforts have to deal with: the need of both universal and orthogonal behaviors. We provide experimental data that clearly indicate that such engineering requirements should not be taken for granted in Synthetic Biology. Electronic supplementary material The online version of this article (doi:10.1186/s1303…

Environmental EngineeringStandardizationOrthogonality (programming)Requirements engineeringComputer scienceBiomedical EngineeringExperimental dataCell BiologyData scienceStandardizationSynthetic biologyWork (electrical)Key (cryptography)Registry of Standard Biological PartsBiobrick partsOrthogonalityLetters to the EditorMolecular BiologySynthetic biologyJournal of Biological Engineering
researchProduct

Estimation of National Colorectal-Cancer Incidence Using Claims Databases

2012

Background.The aim of the study was to assess the accuracy of the colorectal-cancer incidence estimated from administrative data.Methods.We selected potential incident colorectal-cancer cases in 2004-2005 French administrative data, using two alternative algorithms. The first was based only on diagnostic and procedure codes, whereas the second considered the past history of the patient. Results of both methods were assessed against two corresponding local cancer registries, acting as “gold standards.” We then constructed a multivariable regression model to estimate the corrected total number of incident colorectal-cancer cases from the whole national administrative database.Results.The firs…

EstimationArticle SubjectEpidemiologybusiness.industryColorectal cancerIncidence (epidemiology)lcsh:RPublic Health Environmental and Occupational HealthMEDLINElcsh:MedicineRegression analysiscomputer.software_genremedicine.diseaseCancer registryAdministrative databaseStatisticsGeneticsMedicineData miningClaims databasebusinesscomputerResearch ArticleJournal of Cancer Epidemiology
researchProduct

Cartels Uncovered

2018

How many cartels are there? The answer is important in assessing the efficiency of competition policy. We present a Hidden Markov Model that answers the question, taking into account that often we do not know whether a cartel exists in an industry or not. Our model identifies key policy parameters from data generated under different competition policy regimes and may be used with time-series or panel data. We take the model to data from a period of legal cartels - Finnish manufacturing industries 1951 - 1990. Our estimates suggest that by the end of the period, almost all industries were cartelized.

Finnish-Soviet tradekilpailupolitiikkajel:L4001 natural sciencesjel:L41jel:L0jel:L60competition lawjel:L00010104 statistics & probabilitykartellit0502 economics and business050207 economics0101 mathematicsta511lainsäädäntöidänkauppa05 social scienceskorporativismiantitrust policykilpailuoikeuslaitAntitrust; cartel; competition; detection; Hidden Markov models; illegal; legal; leniency; policy; registry.jel:L4antitrust; cartel; competition; detection; Hidden Markov models; illegal; legal; leniency; policy; registrykilpailuGeneral Economics Econometrics and Financecartelscorporatism
researchProduct